Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) CEO Christopher Richard Anzalone sold 24,338 shares of the business’s stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $24.21, for a total transaction of $589,222.98. Following the completion of the transaction, the chief executive officer now directly owns 3,737,000 shares of the company’s stock, valued at $90,472,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Christopher Richard Anzalone also recently made the following trade(s):
- On Monday, September 18th, Christopher Richard Anzalone sold 57,755 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $28.12, for a total transaction of $1,624,070.60.
Arrowhead Pharmaceuticals Stock Down 3.3 %
Arrowhead Pharmaceuticals stock opened at $23.60 on Friday. The stock has a market capitalization of $2.53 billion, a PE ratio of -13.80 and a beta of 1.00. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $23.09 and a twelve month high of $42.48. The company has a 50 day moving average of $26.97 and a 200-day moving average of $31.84.
Institutional Trading of Arrowhead Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 0.8% in the second quarter. BlackRock Inc. now owns 12,811,158 shares of the biotechnology company’s stock worth $456,846,000 after purchasing an additional 100,357 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 0.8% in the third quarter. Vanguard Group Inc. now owns 10,145,990 shares of the biotechnology company’s stock worth $335,325,000 after purchasing an additional 76,653 shares in the last quarter. State Street Corp lifted its position in shares of Arrowhead Pharmaceuticals by 19.2% in the second quarter. State Street Corp now owns 5,582,746 shares of the biotechnology company’s stock worth $196,568,000 after purchasing an additional 900,791 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Arrowhead Pharmaceuticals by 3.2% in the first quarter. JPMorgan Chase & Co. now owns 2,909,965 shares of the biotechnology company’s stock worth $73,913,000 after purchasing an additional 89,143 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in Arrowhead Pharmaceuticals by 4.8% during the fourth quarter. Alliancebernstein L.P. now owns 2,584,693 shares of the biotechnology company’s stock worth $104,835,000 after acquiring an additional 117,633 shares in the last quarter. Institutional investors own 65.98% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have recently commented on ARWR. Royal Bank of Canada reiterated an “outperform” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, August 8th. B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 20th. Citigroup started coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 19th. They set a “neutral” rating and a $33.00 price target for the company. StockNews.com upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $47.00 price objective (down previously from $79.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, August 8th. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $54.53.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.
- Five stocks we like better than Arrowhead Pharmaceuticals
- Bank Stocks – Best Bank Stocks to Invest In
- Is domestic travel back on track? Check out these companies
- Investing in Construction Stocks
- MarketBeat Week in Review – 10/23 – 10/27
- What Does the Consumer Price Index Measure?
- Can casino stocks win big if economy slows?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.